Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNIFY-MS
NCT03364036Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 4 trial of cladribine in multiple sclerosis (MS), sponsored by Merck KGaA. Started May 2018; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03364036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364036.